(2,6-dimethyl-phenyl)-(4'-methyl-4-phenylamino-[1,4']bipiperidinyl-1'-yl)-methanone | 470690-05-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2,6-dimethyl-phenyl)-(4'-methyl-4-phenylamino-[1,4']bipiperidinyl-1'-yl)-methanone
• 英文别名: [4-(4-Anilino-1-piperidyl)-4-methyl-1-piperidyl]-(2,6-dimethylphenyl)methanone；[4-(4-anilinopiperidin-1-yl)-4-methylpiperidin-1-yl]-(2,6-dimethylphenyl)methanone
• CAS: 470690-05-2
• 化学式: C₂₆H₃₅N₃O
• 分子量: 405.583
• InChiKey: MZQMHNMMAJJJCC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  35.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  溴甲苯 、 (2,6-dimethyl-phenyl)-(4'-methyl-4-phenylamino-[1,4']bipiperidinyl-1'-yl)-methanone 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以66%的产率得到(4-(4-(Benzyl(phenyl)amino)piperidin-1-yl)-4-methylpiperidin-1-yl)(2,6-dimethylphenyl)methanone
  参考文献：
  名称：

  Orally Bioavailable Competitive CCR5 Antagonists

  摘要：

  The chemokine receptor CCR5 plays an important role in inflammatory and autoimmune disorders as well as in transplant rejection by affecting the trafficking of effector T cells and monocytes to diseased tissues. Antagonists of CCR5 are believed to be of potential therapeutic value for the disorders mentioned above and HIV infection. Here we report on the structure-activity relationship of a new series of highly potent and selective competitive CCR5 antagonists. While all compounds tested were inactive on rodent CCR5, this series includes compounds that cross-react with the cynomolgus monkey (cyno) receptor. One of these compounds, i.e., 26n, has good PK properties in cynos, and its overall favorable profile makes it a promising candidate for in vivo profiling in transplantation and other disease models.

  DOI：

  10.1021/jm031046g
• 作为产物：
  描述：

  1'-benzyl-4-(2-methoxyethoxy)-[1,4']bipiperidinyl-4'-carbonitrile 在 palladium dihydroxide 盐酸 、 甲酸铵 、 三乙酰氧基硼氢化钠 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 溶剂黄146 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 乙醚 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 71.25h， 生成 (2,6-dimethyl-phenyl)-(4'-methyl-4-phenylamino-[1,4']bipiperidinyl-1'-yl)-methanone
  参考文献：
  名称：

  Orally Bioavailable Competitive CCR5 Antagonists

  摘要：

  The chemokine receptor CCR5 plays an important role in inflammatory and autoimmune disorders as well as in transplant rejection by affecting the trafficking of effector T cells and monocytes to diseased tissues. Antagonists of CCR5 are believed to be of potential therapeutic value for the disorders mentioned above and HIV infection. Here we report on the structure-activity relationship of a new series of highly potent and selective competitive CCR5 antagonists. While all compounds tested were inactive on rodent CCR5, this series includes compounds that cross-react with the cynomolgus monkey (cyno) receptor. One of these compounds, i.e., 26n, has good PK properties in cynos, and its overall favorable profile makes it a promising candidate for in vivo profiling in transplantation and other disease models.

  DOI：

  10.1021/jm031046g

文献信息

• [EN] PIPERIDINE DERIVATIVES AS CCR5 INHIBITORS<br/>[FR] DERIVES DE LA PIPERIDINE, INHIBITEURS DU CCR5
  申请人：NOVARTIS AG

  公开号：WO2004031172A1

  公开（公告）日：2004-04-15

  Disclosed are compounds of formula (I) wherein R1, R2, R3 and X are as defined herein, in free or salt form, which are useful as CCR5 inhibitors, e.g. in the prevention or treatment of disorders mediated by interactions between chemokine receptors and their ligands.

  本发明揭示了公式（I）化合物，其中R1，R2，R3和X的定义如本文所述，以自由或盐形式存在，可用作CCR5抑制剂，例如在预防或治疗由趋化因子受体和其配体之间相互作用介导的疾病中。
• Piperidine derivatives as ccr5 inhibitors
  申请人：Albert Rainer

  公开号：US20060004047A1

  公开（公告）日：2006-01-05

  Disclosed are compounds of formula I: wherein R 1 , R 2 , R 3 and X are as defined herein, in free or salt form, which are useful as CCR5 inhibitors, e.g. in the prevention or treatment of disorders mediated by interactions between chemokine receptors and their ligands.

  本发明涉及式I的化合物：其中R1，R2，R3和X如此定义，以自由或盐形式存在，其可用作CCR5抑制剂，例如在预防或治疗由趋化因子受体与其配体之间相互作用介导的疾病中。
• Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors
  申请人：——

  公开号：US20040142920A1

  公开（公告）日：2004-07-22

  Piperidine derivatives of formula (I) as disclosed in the specification have interesting pharmaceutical properties e.g. as CCR5 inhibitors.

  在说明书中公开的式(I)的吡啶衍生物具有有趣的药理特性，例如作为CCR5抑制剂。
• Piperdine Derivatives as CCR5 Inhibitors
  申请人：ALBERT Rainer

  公开号：US20080249111A1

  公开（公告）日：2008-10-09

  Disclosed are compounds of formula I: wherein R 1 , R 2 , R 3 and X are as defined herein, in free or salt form, which are useful as CCR5 inhibitors, e.g. in the prevention or treatment of disorders mediated by interactions between chemokine receptors and their ligands.

  揭示了式I的化合物：其中R1、R2、R3和X如此定义，以自由或盐形式存在，它们可用作CCR5抑制剂，例如在预防或治疗由趋化因子受体与其配体之间相互作用介导的疾病中。
• Piperidine derivatives as CCR5 inhibitors
  申请人：Novartis AG

  公开号：US07399771B2

  公开（公告）日：2008-07-15

  Disclosed are compounds of formula I: wherein R1, R2, R3 and X are as defined herein, in free or salt form, which are useful as CCR5 inhibitors, e.g. in the prevention or treatment of disorders mediated by interactions between chemokine receptors and their ligands.

  本发明揭示了公式I的化合物：其中R1，R2，R3和X如此定义，以自由或盐形式存在，其可用作CCR5抑制剂，例如在通过趋化因子受体和其配体之间的相互作用介导的疾病的预防或治疗中。